Clinical Trial – Apatinib Combined With Temozolomide – Advanced Melanoma

30 patients with advanced melanoma will receive apatinib plus Temozolomide as maintenance therapy.

Study Type  : Interventional  (Clinical Trial)
Estimated Enrollment  : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Apatinib Combined With Temozolomide in the Treatment of Advanced Melanoma Patients After Conventional Treatment Failure
Actual Study Start Date  : January 8, 2018
Estimated Primary Completion Date  : February 2019
Estimated Study Completion Date  : February 2019
Contacts
Contact: Chuanliang Cui, MD 010-88196317 1008ccl@163.com
Contact: Jun Guo, MD,PHD 010-88196317 guoj307@126.com
Locations
China
Beijing Cancer Hospital Recruiting
Beijing, China
Contact: Jun Guo

 

ClinicalTrials.gov Identifier: NCT03422445
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.